GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - Announces European Medicines Agency has issued a positive scientific opinion on GSK and Vir Biotechnology's sotrovimab, used for the early treatment of Covid-19. EMA's Committee for Human Medicinal Products reviewed all available data on sotrovimab in making decision.
EU member states can use the committee's positive scientific opinion when making national decisions about the early use of sotrovimab prior to EMA marketing authorisation. GlaxoSmithKline says discussions with global regulators regarding authorisations in additional countries "continue to advance".
"As the Covid-19 pandemic continues and the virus generates new variants of concern...the need for therapies that can slow the progression of disease in patients who are at high risk for developing severe complications remains a top priority," says GSK Senior Vice President of Development Christopher Corsico.
"We are encouraged by this positive scientific opinion from the EMA, as it hopefully brings us closer to making sotrovimab available for patients across Europe."
Current stock price: 1,351.85 pence
Year-to-date change: up 0.7%
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)